Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (111-120 of 1,123) with videos related to

Pageof 113
Sort By:
European Urology|January 25, 2006
Natural history and treatment of bone complications in prostate cancerFred Saad, Noel Clarke, Marc Colombel
Current Opinion in Supportive and Palliative Care|July 18, 2018
Treatment of hormone-naïve metastatic prostate cancerZineb Hamilou, Fred Saad, Karim Fizazi
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 19, 2009
The importance of quality indicators: a call to actionLarry Goldenberg, John Trachtenberg, Fred Saad
Urology|August 12, 2017
Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate CancerNeal Shore, Axel Heidenreich, Fred Saad
Current Opinion in Urology|February 7, 2013
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancerJoseph Ischia, Fred Saad, Martin Gleave
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 6, 2024
Establishing maximal wait times for urologic surgery in Canada in 2024Hassan Razvi, Troy Sitland, Fred Saad
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 1, 2025
Update on the state of urology in Canada Results of the 2024 Canadian Urological Association membership surveyHassan Razvi, Troy Sitland, Fred Saad, et al.
BJU International|December 12, 2007
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastasesFred Saad, Richard Markus, Carsten Goessl
Urologic Oncology|January 18, 2006
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasisFred Saad, James McKiernan, James Eastham
European Urology|May 29, 2012
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acidFred Saad, Scott Segal, James Eastham
Pageof 113

Showing results (111-120 of 1,123) with videos related to

Sort By:
Pageof 113
European Urology|January 25, 2006
Natural history and treatment of bone complications in prostate cancerFred Saad, Noel Clarke, Marc Colombel
Current Opinion in Supportive and Palliative Care|July 18, 2018
Treatment of hormone-naïve metastatic prostate cancerZineb Hamilou, Fred Saad, Karim Fizazi
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 19, 2009
The importance of quality indicators: a call to actionLarry Goldenberg, John Trachtenberg, Fred Saad
Urology|August 12, 2017
Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate CancerNeal Shore, Axel Heidenreich, Fred Saad
Current Opinion in Urology|February 7, 2013
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancerJoseph Ischia, Fred Saad, Martin Gleave
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 6, 2024
Establishing maximal wait times for urologic surgery in Canada in 2024Hassan Razvi, Troy Sitland, Fred Saad
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 1, 2025
Update on the state of urology in Canada Results of the 2024 Canadian Urological Association membership surveyHassan Razvi, Troy Sitland, Fred Saad, et al.
BJU International|December 12, 2007
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastasesFred Saad, Richard Markus, Carsten Goessl
Urologic Oncology|January 18, 2006
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasisFred Saad, James McKiernan, James Eastham
European Urology|May 29, 2012
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acidFred Saad, Scott Segal, James Eastham
Pageof 113